T A Johnson Selected Research

Bromides

1/2000

Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

T A Johnson Research Topics

Disease

2	B-Cell Lymphoma (Lymphoma, B Cell) 04/2000 - 01/2000
1	Infections 02/2011
1	Multiple Sclerosis 02/2011
1	X-linked Reticuloendotheliosis 06/2007
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2000
1	Lymphoma (Lymphomas) 01/2000
1	Neoplasms (Cancer) 01/2000

Drug/Important Bio-Agent (IBA)

2	Monoclonal AntibodiesIBA 04/2000 - 01/2000
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 02/2011
1	AntigensIBA 02/2011
1	Fingolimod Hydrochloride (FTY720)FDA Link 02/2011
1	Sphingosine-1-Phosphate ReceptorsIBA 02/2011
1	Proteins (Proteins, Gene)FDA Link 06/2007
1	Immunoconjugates (Immunoconjugate)IBA 04/2000
1	B-Lymphocyte Differentiation Antigens (Antigens, Differentiation, B Lymphocyte)IBA 04/2000
1	Coloring Agents (Dyes)IBA 01/2000
1	AntibodiesIBA 01/2000
1	BromidesIBA 01/2000
1	Iodine-131IBA 01/2000
1	Trypan Blue FDA Link 01/2000

Therapy/Procedure

1	Therapeutics 04/2000
1	Drug Therapy (Chemotherapy) 01/2000